Login to Your Account



Financings Roundup

The 'Rights' Stuff: Offering Gains Pharmacyclics $24M

By Jennifer Boggs


Friday, July 17, 2009
Rebounding from its 2007 troubles with lung cancer drug Xcytrin, Pharmacyclics Inc. has emerged with a retooled management team, a multiproduct pipeline and a rather unusual - at least for biotech - money-raising strategy. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription